PedAM
Pediatric Disease Annotations & Medicines
| Disease | constipation |
| Symptom | C0022104|irritable bowel syndrome |
| Sentences | 56 |
| PubMedID- 24660576 | Treatment of constipation-predominant irritable bowel syndrome by focusing on the liver in terms of traditional chinese medicine: a meta-analysis. |
| PubMedID- 23090647 | Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 25545101 | Breath methane correlates with levels of constipation in irritable bowel syndrome (ibs) but methanogens numbers are depleted in ibd 2. |
| PubMedID- 25726441 | irritable bowel syndrome with constipation), worries and concerns (irritable bowel syndrome with constipation vs. |
| PubMedID- 24943204 | Background: historically, measures of symptom severity of irritable bowel syndrome with constipation (ibs-c) in clinical trials have not met the evidence requirements described in the fda guidance on patient-reported outcomes (pros), which describes the evidentiary requirements and review criteria for patient-reported outcome measures intended to support product approval or labelling claims. |
| PubMedID- 24433216 | irritable bowel syndrome with constipation is a prevalent, functional bowel disorder that causes a substantial burden to patients and society.65, 66 while a large armamentarium of treatment options for ibs-c is available, the majority of these options lack proven efficacy from clinical trial data and/or have unfavourable side-effect profiles. |
| PubMedID- 26579459 | The u. s. fda has approved 290 μg of linaclotide daily for irritable bowel syndrome with constipation and 145 μg daily for chronic idiopathic constipation38. |
| PubMedID- 20050846 | Tegaserod (teg), a 5-hydroxytryptamine type-4 (5-ht(4)) receptor partial agonist, represents a novel treatment for irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 23162373 | Burden of constipation-predominant irritable bowel syndrome (ibs-c) in france, italy, and the united kingdom. |
| PubMedID- 21324760 | Results: stool form was significantly different in the irritable bowel syndrome patients with diarrhoea or constipation, and bowel movements were more frequent in the irritable bowel syndrome patients than in the healthy subjects. |
| PubMedID- 25781368 | Introduction: the irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are associated with substantial symptom and disease burden. |
| PubMedID- 26533548 | The burden of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in france: a comparison with the european results from the ibis-c observational study. |
| PubMedID- 25538778 | The effect of biofeedback therapy on dyssynergic constipation in patients with or without irritable bowel syndrome. |
| PubMedID- 24252578 | Results: of the 128 consecutive, constipated patients included (84% females, mean age 49.7 +/- 15.5 years) 66 suffered from irritable bowel syndrome with constipation and 62 from functional constipation. |
| PubMedID- 21902826 | Our patient also had a history of chronic constipation that was attributed to irritable bowel syndrome, and had been treated with laxatives and prokinetics without lasting success. |
| PubMedID- 24684643 | Background: the prevalence of irritable bowel syndrome with constipation (ibs-c) is estimated to be between 4.3% and 5.2% among adults in the united states. |
| PubMedID- 25653859 | Background: optimal clinical trial endpoints for irritable bowel syndrome with constipation (ibs-c) are uncertain. |
| PubMedID- 21848795 | Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the systematic investigation of gastrointestinal diseases in china (silc). |
| PubMedID- 23859757 | Hence, there remains an unmet need for well-tolerated and effective treatments for irritable bowel syndrome with constipation that target abdominal symptoms, including abdominal pain and bowel symptoms. |
| PubMedID- 20200325 | Objectives: tegaserod, a partial 5-ht(4) agonist previously approved for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, was suspended from us marketing in 2007, based on pooled clinical trial results which contained a signal suggesting increased risk of cardiovascular ischemic events (cvies). |
| PubMedID- 26016701 | irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are two common functional gastrointestinal disorders that impair quality of life and pose a significant economic burden to the health care system. |
| PubMedID- 25237424 | Background: irritable bowel syndrome with constipation (ibs-c), a chronic functional gastrointestinal disorder, has been shown to negatively affect work productivity and impair daily activity, resulting in a substantial burden for patients and employers. |
| PubMedID- 24833940 | Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. |
| PubMedID- 23598923 | Recently, si- ni-san has been shown to alleviate irritable bowel syndrome of the constipation predominant type, decrease palmoplantar perspiration in palmoplantarhidrosis, reduce blood glucose, and improve insulin resistance. |
| PubMedID- 23672677 | In the present issue of neurogastroenterology & motility, the performance of the fda responder endpoint for clinical trials in irritable bowel syndrome with constipation was evaluated using data from two large phase iii clinical trials of linaclotide. |
| PubMedID- 22847198 | Material/methods: thirty patients with a diagnosis of constipation-predominant irritable bowel syndrome and 30 healthy volunteers were included in the study. |
| PubMedID- 24833931 | irritable bowel syndrome with constipation (ibs-c) affects approximately 5% of the population in western countries. |
| PubMedID- 23116208 | Background: treatment options that improve overall symptoms of irritable bowel syndrome with constipation (ibs-c) are lacking. |
| PubMedID- 24693271 | New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 26533542 | Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 20163375 | Background: renzapride, a 5-hydroxytryptamine type-4 (5-ht(4)) receptor agonist and 5-ht(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (ibs-c). |
| PubMedID- 22251419 | Background: irritable bowel syndrome with constipation (ibs-c) significantly decreases quality of life and the ability to perform daily living activities. |
| PubMedID- 24007408 | Introduction: irritable bowel syndrome with constipation (ibs-c) is associated with abdominal pain and infrequent spontaneous bowel movements. |
| PubMedID- 26294923 | By the nature of altered bowel habits, ibs is classified into subtypes including ibs-c, irritable bowel syndrome with constipation; ibs-d, irritable bowel syndrome with diarrhoea; ibs-m, mixed irritable bowel syndrome (with both diarrhea and constipation >25% of bowel movements); and ibs-a, alternating irritable bowel syndrome (bowel habits often vary over time) 1. |
| PubMedID- 24623286 | The high number of constipation predominant irritable bowel syndrome and very low number of diarrhea predominant irritable bowel syndrome patients might be the reason for statistical non-significance since alpha2-adrenergic receptor gene is found to be responsible for mediating intestinal antisecretory action and probably is involved in the pathogenesis of diarrhea predominant irritable bowel syndrome. |
| PubMedID- 24001336 | Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. |
| PubMedID- 20863829 | These results suggest that the guanylate cyclase c agonist linaclotide elicits potent pharmacological responses locally in the gastrointestinal tract, and that orally administered guanylate cyclase c agonists may be capable of improving bowel habits in patients suffering from irritable bowel syndrome with constipation and chronic constipation. |
| PubMedID- 21765950 | Tegaserod is an agonist of the serotonin receptor 5-hydroxytryptamine 4 (5-ht4) and has been used for treating chronic constipation in patients with irritable bowel syndrome and chronic idiopathic constipation , . |
| PubMedID- 23641133 | Linaclotide (linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. |
| PubMedID- 24090017 | The european medicines agency has authorized its indication for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. |
| PubMedID- 26555695 | Peptide-based therapeutics have been successfully developed against other molecular targets, as exemplified by the approval of pasireotide (signifor) for the treatment of cushing’s disease and the disulfide-rich linaclotide (linzess®) for the treatment of irritable bowel syndrome with constipation (ibs-c) and idiopathic and chronic constipation . |
| PubMedID- 24840367 | irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. |
| PubMedID- 26028974 | Optimal management of constipation associated with irritable bowel syndrome. |
| PubMedID- 22963061 | Lubiprostone is effective for the treatment of constipation-predominant irritable bowel syndrome, and alosetron (restrictions for use apply in the united states) and tegaserod (available only for emergency use in the united states) are approved for patients with severe symptoms in whom conventional therapy has been ineffective. |
| PubMedID- 23816770 | Background: irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are common functional bowel disorders. |
| PubMedID- 26533504 | Economic burden and quality of life of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in germany: results from the ibis-c study. |
| PubMedID- 23835436 | Randomized clinical trial: macrogol/peg 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. |
| PubMedID- 24812563 | The study of ardatskaia on 30 patients having irritable bowel syndrome with predominance of constipation showed that normoflorin therapy had normalized the intestinal motor activity through changes in microbial flora of the intestines . |
| PubMedID- 23710967 | irritable bowel syndrome (ibs) with constipation was associated with pain in the left flank and patients were less likely to report pain in the right hypochondrium. |
| PubMedID- 22444104 | Apart from lubiprostone, treatment of irritable bowel syndrome with constipation is limited to small studies (with poor descriptions of side effects), although lubiprostone and selective serotonin reuptake inhibitors appear safe. |
Page: 1 2